Inhibition of CTL Induction by Rapamycin: IL-2 Rescues Granzyme B and Perforin Expression but only Partially Restores Cytotoxic Activity

Journal of Immunology

Volumn 159, Issue 10, 1997, Pages 4700-4707

  Makrigiannis, Andrew P ^a   Hoskin, David W ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; GRANZYME; GZMB PROTEIN, MOUSE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PERFORIN; POLYENE; PORE FORMING CYTOTOXIC PROTEIN; RAPAMYCIN; RECOMBINANT PROTEIN; SERINE PROTEINASE;

ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION; GRANZYMES; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; POLYENES; PORE FORMING CYTOTOXIC PROTEINS; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES; SIROLIMUS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031573158     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Seghal, S. N., H. Baker, and C. Vezina. 1975. Rapamycin (AY-22, 989), a new anti-fungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28:727.
2. Terada, N., K. Takase, P. Papst, A. C. Nairn, and E. W. Gelfand. 1995. Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation in mitogen-activated T lymphocytes. J. Immunol. 155:3418.
3. Kay, J. E., L. Kromwell, S. E. A. Doe, and M. Denyer. 1991. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 72:544.
4. Kuo, C. J., J. Chung, D. F. Florentino, W. M. Flanagan, J. Blenis, and G. R. Crabtree. 1992. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358:70.
5. Bierer, B. E., P. S. Mattila, R. F. Standaert, L. A. Herzenberg, S. J. Burakoff, G. Crabtree, and S. L. Schreiber. 1990. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. USA 87:9231.
6. Brown, E. J., M. W. Albers, T. B. Shin, K. Ichikawa, C. T. Keith, W. S. Lane, and S. L. Schreiber. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756.
7. Brown, E. J., P. A. Beal, C. T. Keith, J. Chen, T. B. Shin, and S. L. Schreiber. 1995. Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature 377:441.
8. Proud, C. G. 1996. p70 S6 kinase: an enigma with variations. Trends Biochem. Sci. 21:181.
9. Smith, K. A. 1988. Interleukin-2: inception, impact, and implications. Science 240:1169.
10. Lui, C.-C., S. V. Joag, B. S. Kwon, and J. Ding-E. Young. 1990. Induction of perform and serine esterases in a mouse cytotoxic T lymphocyte clone. J. Immunol. 144:1196.
11. Suda, T., T. Okazaki, Y. Naito, T. Yokota, N. Arai, S. Ozaki, K. Nakao, and S. Nagata. 1995. Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 154:3806.
12. Heusel, J. W., R. L. Wesselschmidt, S. Shresta, J. H. Russell, and T. J. Ley. 1994. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76:977.
13. Kagi, D., F. Vignaux, B. Ledermann, K. Burki, V. Depraetere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528.
14. Leros-Maida, S., A. Soulie, C. Benvenuti, A. Wargnier, N. Vallee, C. Berthou, J. Guillet, M. Sasportes, and N. Sigaux. 1994. Granzyme B and perform can be used as predictive markers of acute rejection in heart transplantation. Eur. J. Immunol. 24:229.
15. Lipman, M. L., A. C. Stevens, and T. B. Strom. 1994. Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J. Immunol. 152:5120.
16. Darmon, A. J., D. W. Nicholson, and R. C. Bleackley. 1995. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377: 446.
17. Enari, M., H. Hug, and S. Nagata. 1995. Involvement of an ICE-like protease in fas-mediated apoptosis. Nature 375:78.
18. Vignaux, F., and P. Golstein. 1994. Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway. Eur. J. Immunol. 24:923.
19. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630.
20. Hutchinson, I. 1991. Cellular mechanisms of allograft rejection. Curr. Opin. Immunol. 3:722.
21. Morris, R. E., B. M. Meiser, J. Wu, R. Shorthouse, and J. Wang. 1991. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporin, and FK 506, and effect of host-versus-graft and graft-versus-host reactions. Transplant. Proc. 23:521.
22. Kahan, B. D., S. Gibbons, N. Tejpal, S. M. Stepkowski, and T.-C. Chou. 1991. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 51:232.
23. Leo, O., M. Foo, D. H. Sachs, L. E. Samelson, and J. A. Bluestone. 1987. Identification of a monoclonal antibody specific to a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA 84:1374.
24. Yagita, H., T. Nakamura, H. Karasuyama, and K. Okumura. 1989. Monoclonal antibodies specific for murine CD2 reveal its presence on B as well as T cells. Proc. Natl. Acad. Sci. USA 86:645.
25. Julius, M. H., E. Simpson, and L. A. Herzenberg. 1973. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur. J. Immunol. 3:645.
26. Okamoto, T., M. Harada, Y. Shinomiya, G. Matsuzaki, and K. Nomoto. 1995. The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 antibody and activated B cells as costimulatory-signal-providing cells. Cancer Immunol. Immunother. 40:173.
27. Fitzpatrick, L., A. P. Makrigiannis, M. Kaiser, and D. W. Hoskin. 1996. Anti-CD3-activated killer T cells: interferon-gamma and interleukin-10 cross-regulate granzyme B expression and the induction of major histocompatibility complex-unrestricted cytotoxicity. J. Interferon Cytokine Res. 16:537.
28. Lobe, C. G., B. B. Finlay, W. Paranchych, V. H. Paetkau, and R. C. Bleackley. 1986. Novel serine proteases encoded by two cytotoxic T lymphocyte-specific genes. Science 232:858.
29. Nakajima, F., A. Khanna, G. Xu, M. Lagman, R. Haschemeyer, J. Mouradian, J. C. Wang, K. H. Stenzel, A. L. Rubin, and M. Suthanthiran. 1994. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. Proc. Natl. Acad. Sci. USA 91:7889.
30. Arase, H., N. Arase, and T. Saito. 1995. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181:1235.
31. Takahashi, T., M. Tanaka, C. I. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969.
32. Ishikawa, H., Y.-I. Shinkai, H. Yagita, C. C. Yue, P. A. Henkart, S. Sawada, H. A. Young, C. W. Reynolds, and K. Okumura. 1989. Molecular cloning of rat cytolysin. J. Immunol. 143:3069.
33. Singer-Sam, J., M. O. Robinson, A. R. Bellvè, M. I. Simon, and A. P. Riggs. 1990. Measurement by quantitative PCR of changes in HPRT, PGK-1, PGK-2, APRT, Mtase and Zfy gene transcripts during mouse spermatogenesis. Nucleic Acids Res. 18:1255.
34. Poe, M., J. T. Blake, D. A. Boulton, M. Gammon, N. H. Sigal, J. K. Wu, and H. J. Zweerink. 1991. Human cytotoxic lymphocyte granzyme B: its purification from granules and the characterization of substrate and inhibitor specificity. J. Biol. Chem. 266:98.
35. Kaiser, M., and D. W. Hoskin. 1992. Expression and utilization of chymotrypsin-like but not trypsin-like serine protease enzymes by nonspecific T killer cells activated by anti-CD3 monoclonal antibody. Cell. Immunol. 141:84.
36. Kaiser, M., J. Brooks-Kaiser, L. Filzpatrick, R. C. Bleackley, and D. W. Hoskin. 1993. Cytotoxic cell proteinase gene expression and cytolytic activity by anti-CD3-activated cytotoxic T lymphocytes is sensitive to cyclosporin A but is not dependent on interleukin-2 synthesis. J. Leukocyte Biol. 54:458.
37. Stohl, W., Z. Tovar, and N. Talal. 1990. Generation of cytolytic activity with anti-CD3 monoclonal antibodies involves both IL-2-independent and -dependent components. J. Immunol. 144:3718.
38. Robinet, E., D. Branellec, A. M. Termijtelen, J. Y. Blay, F. Gay, and S. Chouaib. 1990. Evidence for tumor necrosis factor-α involvement in the optimal induction of class I allospecitic cytotoxic T cells. J. Immunol. 144:4555.
39. Terada, N., H. R. Patel, K. Takase, K. Kohno, A. C. Nairn, and E. W. Gelfand. 1994. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc. Natl. Acad. Sci. USA 91:11477.
40. Stewart, B. H., and D. W. Hoskin. 1997. Inhibition of protein tyrosine kinases or protein kinase C prevents nonspecific killer T lymphocyte-mediated tumoricidal activity. Biochim. Biophys. Acta 1356:331.
41. Woerly, G., N. Brooks, and B. Ryffel. 1996. Effect of rapamycin on the expression of the IL-2 receptor (CD25). Clin. Exp. Immunol. 103:322.
42. Granger, D. K., J. W. Cromwell, S. C. Chen, J. J. Goswitz, D. T. Morrow, F. A. Beierle, S. N. Sehgal, D. M. Canafax, and A. J. Matas. 1995. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 59:183.
43. Chen, H., D. Xu, S. Qi, J. Wu, H. Luo, and P. Daloze. 1995. Rapamycin graft pretreatment in small bowel and kidney transplantation in the rat. Transplantation 59:1084.
44. Anel, A., M. Buferne, C. Boyer, A.-M. Schmitt-Verhulst, and P. Golstein. 1994. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur. J. Immunol. 24:2469.
45. Garner, R., C. D. Helgason, E. A. Atkinson, M. J. Pinkoski, H. L. Ostergaard, O. Sorensen, A. Fu, P. H. Lapchak, A. Rabinovitch, J. E. McElhaney, G. Berke, and R. C. Bleackley. 1994. Characterization of a granule-independent lytic mechanism used by CTL hybridomas. J. Immunol. 153:5413.
46. Larsen, C. P., D. Z. Alexander, R. Hendrix, S. Ritchie, and T. C. Pearson. 1995. Fas-mediated cytotoxicity: an immunoeffector or immunoregulatory pathway in T cell-mediated immune responses? Transplantation 60:221.
47. Miyazaki, T., Z.-J. Liu, A. Kawahara, Y. Minami, K. Yamada, Y. Tsujimoto, E. L. Barsoumian, R. M. Perlmutter, and T. Taniguchi. 1995. Three distinct IL-2 signalling pathways mediated by bcl-2. c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 81:223.
48. lck: identification of novel inter-molecular association. Science 252:1523.
49. Shibuya, H., M. Yoneyama, J. Ninomiya-Tsuji, K. Matsumoto, and T. Taniguchi. 1992. IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signalling pathways: demonstration of a novel role for c-myc. Cell 70:57.
50. Wakao, H., N. Harada, T. Kitamura, A. L.-F. Mui, and A. Miyajima. 1995. Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J. 14:2527.
51. de Groot, R. P., L. M. Ballou, and P. Sassone-Corsi. 1994. Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell 79:81.
52. Feuerstein, N., D. Huang, S. H. Hinrichs, D. J. Orten, N. Aiyar, and M. B. Prystowsky. 1995. Regulation of cAMP-responsive enhancer binding proteins during cell cycle progression in T lymphocytes stimulated by IL-2. J. Immunol. 154:68.
53. Lobe, C. G., J. Shaw, C. Fregeau, B. Duggan, M. Meier, A. Brewer, C. Upton, G. McFadden, R. K. Patient, V. Paetkau, and R. C. Bleackley. 1989. Transcriptional regulation of two cytotoxic T lymphocyte-specific serine protease genes. Nucleic Acids Res. 17:5765.
54. Youn, B.-S., C.-C. Liu, K.-K. Kim, J. D.-E. Young, M. H. Kwon, and B. Kwon, 1991. Structure of the mouse pore-forming protein (perform) gene: analysis of transcription initiation site, 5′ flanking sequence, and alternative splicing of 5′ untranslated regions. J. Exp. Med. 173:813.
55. Hanson, R. D., J. L. Grisolano, and T. J. Ley. 1993. Consensus AP-1 and CRE motifs upstream from the human cytotoxic serine protease B (CSP-B/CGL-1) gene synersize to activate transcription. Blood 82:2749.
56. Xing, J., D. D. Ginty, and M. E. Greenberg. 1996. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273:959.
57. Terada, N., R. A. Franklin, J. J. Lucas, J. Blenis, and G. W. Gelfand. 1993. Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J. Biol. Chem. 268:12062.
58. Haddad, P., A. Wargnier, J.-F. Bourge, M. Sasportes, and P. Paul. 1993. A promoter element of the human serine esterase granzyme B gene controls specific transcription in activated T cells. Eur. J. Immunol. 23:625.
59. Beadling, C., J. Ng, J. W. Babbage, and D. A. Cantrell. 1996. Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway. EMBO J. 15:1902.
60. Gaffen, S. L., S. Y. Lai, W. Xu, F. Gouilleux, B. Groner, M. A. Goldsmith, and W. C. Greene. 1995. Signalling through the interleukin 2 receptor beta chain activates a STAT-5-like DNA binding activity. Proc. Natl. Acad. Sci. USA 92: 7192.